Alnylam halts hemophilia drug trial due to patient death, renewing worries over safety By: Boston Business Journal via Business Journals September 07, 2017 at 10:29 AM EDT The announcement by the Cambridge biotech on Thursday cut its market cap by around $1 billion. Read More >>